E10K2

E10K2 is an investigational oncolytic virus therapy being developed by Guangzhou Double Bioproducts (also known as Guangzhou Dabao Bioproducts). As an oncolytic virus, it is designed to selectively infect and replicate within tumor cells, leading to direct cell lysis and the potential release of tumor-associated antigens that can stimulate a systemic anti-tumor immune response. E10K2 is part of the company's 'E10' series of recombinant viral and gene therapies, which includes other adenovirus-based candidates like E10A and E10B. While specific details regarding its viral backbone and any potential therapeutic transgenes have not been fully disclosed, it is positioned within the pipeline for the treatment of malignant tumors.